Clinical Trial

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 10, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-22; most recent amendment 2025-11-05.
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06008275
Lead Sponsor Baylor Research Institute
Conditions Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Enrollment 20 participants
Start Date 2024-09-16
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-10